Decision Making SIG


The Quantitative Decision-making Special Interest Group (QDM SIG) was formed in October 2017. It is a group of statisticians from industry and academia, with experience and interests in statistical methods for quantitative decision-making in drug development. The objectives of the SIG are:

  • To share (anonymized) case studies of how quantitative decision-making methods have been used within pharmaceutical companies, for decisions at the trial level, at the development level and at the portfolio level
  • To perform literature reviews, discuss and make recommendations on existing methodologies in terms of approach and interpretation
  • To develop new methodologies or practices where needed
  • To promote the role of the statistician in supporting decision-making in pharmaceutical companies and/or other stakeholders
  • To propose trainings, public meetings or publications to share methods and experience

Who we are

Thomas Blondel (Ceva)
Nicolas Bonnet (Sanofi)
Daniel Bratton (GSK)
Sarah Bray (Amgen)
Alex Carlton (GSK) (Co-Chair)
Jacquie Christie (Sobi)
Paul Frewer (AstraZeneca)
Heiko Goette (Merck)
Tadhg Guerin (Theravance) (Co-Chair)
Kimberley Hacquoil (Exploristics)
Martin Johnson (UCB Pharma)
Kevin Kunzmann (Boehringer Ingelheim)
John-Philip Lawo (CSL Behring)
Daniel Leibovitz (Incyte)
Jesper Madsen (Novo Nordisk)
Pavel Mozgunov (Cambridge University)
Emmanuel Pham (Nova Discovery)
Gustaf Rydevik (UCB Pharma)
Gaëlle Saint-Hilary (Saryga)
Guido Thömmes (Merck)
Katie Thorn (GSK)
Stefano Vezzoli (Chiesi Farmaceutici)
Stig Johan Wiklund (Captario)
Corine Baayen (Lundbeck)

Lasse Breuning Sluth (Lundbeck)

Caroline Petit

Gilles Guillot (CSL Behring)

How to get in touch

For further information, or to join the QDM SIG, please contact our Co-Chairs:

Alex Carlton (GSK)
Tadhg Guerin (Theravance)

Latest News


Upcoming Events


Upcoming Events

Latest Jobs